{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:12:18Z","timestamp":1769098338539,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T00:00:00Z","timestamp":1389312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1038\/ijo.2014.2","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T08:48:04Z","timestamp":1389343684000},"page":"1165-1171","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease"],"prefix":"10.1038","volume":"38","author":[{"given":"R V","family":"Seimon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Ivers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Finer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U F","family":"Legler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W P T","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I D","family":"Caterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,10]]},"reference":[{"key":"BFijo20142_CR1","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1016\/S0140-6736(05)67663-5","volume":"366","author":"S Yusuf","year":"2005","unstructured":"Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P et al. Obesity and the risk of myocardial infarction in 27\u2009000 participants from 52 countries: a case-control study. Lancet 2005; 366: 1640\u20131649.","journal-title":"Lancet"},{"key":"BFijo20142_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/acprof:oso\/9780198525738.003.0011","volume-title":"Coronary Heart Disease Epidemiology: From Aetiology to Public Health","author":"CMM Lawes","year":"2005","unstructured":"Lawes CMM, Hoorn SV, Elliott P, Rodgers A . Blood pressure and the burden of coronary heart disease. In: Marmot M, Elliott P (eds). Coronary Heart Disease Epidemiology: From Aetiology to Public Health, 2nd edn. Oxford University Press: Oxford, UK, 2005, pp 152\u2013173."},{"key":"BFijo20142_CR3","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","volume":"289","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560\u20132572.","journal-title":"JAMA"},{"key":"BFijo20142_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","volume":"28","author":"I Graham","year":"2007","unstructured":"Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375\u20132414.","journal-title":"Eur Heart J"},{"key":"BFijo20142_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.7326\/0003-4819-142-7-200504050-00011","volume":"142","author":"V Snow","year":"2005","unstructured":"Snow V, Barry P, Fitterman N, Qaseem A, Weiss K . Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142: 525\u2013531.","journal-title":"Ann Intern Med"},{"key":"BFijo20142_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1463-1326.2011.01554.x","volume":"14","author":"ID Caterson","year":"2012","unstructured":"Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523\u2013530.","journal-title":"Diabetes Obes Metab"},{"key":"BFijo20142_CR7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa066254","volume":"357","author":"L Sj\u00f6str\u00f6m","year":"2007","unstructured":"Sj\u00f6str\u00f6m L, Narbro K, Sj\u00f6str\u00f6m CD, Karason K, Larsson B, Wedel H et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741\u2013752.","journal-title":"N Engl J Med"},{"key":"BFijo20142_CR8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa066603","volume":"357","author":"TD Adams","year":"2007","unstructured":"Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357: 753\u2013761.","journal-title":"N Engl J Med"},{"key":"BFijo20142_CR9","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/bmj.333.7572.794","volume":"333","author":"M Lean","year":"2006","unstructured":"Lean M, Finer N . ABC of obesity. Management: part II\u2014drugs. BMJ 2006; 333: 794\u2013797.","journal-title":"BMJ"},{"key":"BFijo20142_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1177\/0269881108095195","volume":"24","author":"JC Halford","year":"2010","unstructured":"Halford JC, Boyland EJ, Cooper SJ, Dovey TM, Huda MS, Dourish CT et al. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J Psychopharmacol 2010; 24: 99\u2013109.","journal-title":"J Psychopharmacol"},{"key":"BFijo20142_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.clpt.2006.02.002","volume":"79","author":"K Heusser","year":"2006","unstructured":"Heusser K, Tank J, Diedrich A, Engeli S, Klaua S, Kr\u00fcger N et al. Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin Pharmacol Ther 2006; 79: 500\u2013508.","journal-title":"Clin Pharmacol Ther"},{"key":"BFijo20142_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.neuro.2005.09.004","volume":"27","author":"F Lechin","year":"2006","unstructured":"Lechin F, van der Dijs B, Hernandez G, Orozco B, Rodriguez S, Baez S . Neurochemical, neuroautonomic and neuropharmacological acute effects of sibutramine in healthy subjects. Neurotoxicology 2006; 27: 184\u2013191.","journal-title":"Neurotoxicology"},{"key":"BFijo20142_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa1003114","volume":"363","author":"WP James","year":"2010","unstructured":"James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905\u2013917.","journal-title":"N Engl J Med"},{"key":"BFijo20142_CR14","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/eurheartj\/ehm217","volume":"28","author":"C Torp-Pedersen","year":"2007","unstructured":"Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 2915\u20132923.","journal-title":"Eur Heart J"},{"key":"BFijo20142_CR15","doi-asserted-by":"publisher","first-page":"L44","DOI":"10.1093\/eurheartj\/sui086","volume":"7","author":"WP James","year":"2005","unstructured":"James WP . The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. Eur Heart J Suppl 2005; 7: L44\u2013L48.","journal-title":"Eur Heart J Suppl"},{"key":"BFijo20142_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1463-1326.2008.00930.x","volume":"11","author":"AM Sharma","year":"2009","unstructured":"Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP et al. Blood pressure changes associated with sibutramine and weight management\u2014an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 2009; 11: 239\u2013250.","journal-title":"Diabetes Obes Metab"},{"key":"BFijo20142_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-134-1-200101020-00007","volume":"134","author":"VJ Stevens","year":"2001","unstructured":"Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, Smith West D et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1\u201311.","journal-title":"Ann Intern Med"},{"key":"BFijo20142_CR18","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1056\/NEJM198104163041602","volume":"304","author":"ML Tuck","year":"1981","unstructured":"Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M . The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930\u2013933.","journal-title":"N Engl J Med"},{"key":"BFijo20142_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2217\/pgs.11.137","volume":"13","author":"W Zhang","year":"2012","unstructured":"Zhang W, Roederer MW, Chen WQ, Fan L, Zhou HH . Pharmacogenetics of drugs withdrawn from the market. Pharmacogenomics 2012; 13: 223\u2013231.","journal-title":"Pharmacogenomics"},{"key":"BFijo20142_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.amjmed.2007.05.011","volume":"120","author":"S Uretsky","year":"2007","unstructured":"Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Medicine 2007; 120: 863\u2013870.","journal-title":"Am J Medicine"},{"key":"BFijo20142_CR21","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehp162","volume":"30","author":"TE Strandberg","year":"2009","unstructured":"Strandberg TE, Strandberg AY, Salomaa VV, Pitk\u00e4l\u00e4 KH, Tilvis RS, Sirola J et al. Explaining the obesity paradox: cardiovascular risk, weight change, and mortality during long-term follow-up in men. Eur Heart J 2009; 30: 1720\u20131727.","journal-title":"Eur Heart J"},{"key":"BFijo20142_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/eurheartj\/ehs217","volume":"34","author":"O Anger\u00e5s","year":"2013","unstructured":"Anger\u00e5s O, Albertsson P, Karason K, R\u00e5munddal T, Matejka G, James S et al. Evidence for obesity paradox in patients with acute coronary syndromes: a report from the Swedish Coronary Angiography and Angioplasty Registry. Eur Heart J 2013; 34: 345\u2013353.","journal-title":"Eur Heart J"},{"key":"BFijo20142_CR23","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1093\/eurheartj\/ehp288","volume":"30","author":"A Oreopoulos","year":"2009","unstructured":"Oreopoulos A, McAlister FA, Kalantar-Zadeh K, Padwal R, Ezekowitz JA, Sharma AM et al. The relationship between body mass index, treatment, and mortality in patients with established coronary artery disease: a report from APPROACH. Eur Heart J 2009; 30: 2584\u20132592.","journal-title":"Eur Heart J"},{"key":"BFijo20142_CR24","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","volume":"362","author":"WC Cushman","year":"2010","unstructured":"Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA et al. ACCORD Study Group Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575\u20131585.","journal-title":"N Engl J Med"},{"key":"BFijo20142_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1001\/jama.2010.884","volume":"304","author":"RM Cooper-DeHoff","year":"2010","unstructured":"Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61\u201368.","journal-title":"JAMA"},{"key":"BFijo20142_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrcardio.2010.182","volume":"8","author":"RM Cooper-DeHoff","year":"2011","unstructured":"Cooper-DeHoff RM, Egelund EF, Pepine CJ . Blood pressure lowering in patients with diabetes\u2014one level might not fit all. Nat Rev Cardiol 2011; 8: 42\u201349.","journal-title":"Nat Rev Cardiol"},{"key":"BFijo20142_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s10286-005-0270-y","volume":"15","author":"AL Birkenfeld","year":"2005","unstructured":"Birkenfeld AL, Schroeder C, Pischon T, Tank J, Luft FC, Sharma AM et al. Paradoxical effect of sibutramine on autonomic cardiovascular regulation in obese hypertensive patients\u2014sibutramine and blood pressure. Clin Auto Res 2005; 15: 200\u2013206.","journal-title":"Clin Auto Res"},{"key":"BFijo20142_CR28","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.amjcard.2004.04.043","volume":"94","author":"WB Kannel","year":"2004","unstructured":"Kannel WB, Wilson PW, Nam BH, D\u2019Agostino RB, Li J . A likely explanation for the J-curve of blood pressure cardiovascular risk. Am J Cardiol 2004; 94: 380\u2013384.","journal-title":"Am J Cardiol"},{"key":"BFijo20142_CR29","doi-asserted-by":"publisher","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","volume":"144","author":"FH Messerli","year":"2006","unstructured":"Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Internal Med 2006; 144: 884\u2013893.","journal-title":"Ann Internal Med"},{"key":"BFijo20142_CR30","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.jacc.2009.05.073","volume":"54","author":"FH Messerli","year":"2009","unstructured":"Messerli FH, Panjrath GS . The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 2009; 54: 1827\u20131834.","journal-title":"J Am Coll Cardiol"}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ijo20142","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo20142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ijo20142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T19:03:53Z","timestamp":1647371033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ijo20142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,10]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["BFijo20142"],"URL":"https:\/\/doi.org\/10.1038\/ijo.2014.2","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,10]]},"assertion":[{"value":"23 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NF: member of SCOUT ESC received payments from Abbott, as advisor for Novo Nordisk, Merck, sanofi-aventis, GlaxoSmithKline and Shionogi, consultant for Ajinomoto, and provided expert testimony for sanofi-aventis, Vivus, Arena and received a grant from GlaxoSmithKline. UFL was an employee of Abbott with equity interest in the Company. AMS is the member of the SCOUT ESC received payment from Abbott Laboratories, and is an advisor for Abbott, Merck, Arena, Novo-Nordisk, sanofi-aventis, GlaxoSmithKline, Boehringer Ingelheim and NeuroSearch, as a consultant for Vivus and Allegan, provided expert testimony for GlaxoSmithKline, received grants from Abbott and Covidian. WPTJ: Chair of the SCOUT ESC received payment from Abbott; the International Association for the Study of Obesity of which he is the President, he also received a grant from Novo Nordisk. WC is the member of the SCOUT ESC, received payments from Abbott Laboratories, lecture fees and\/or travel reimbursement from Abbott, Ache Laboratorios Farmaceuticos S\/A, Roche and Novo Nordisk, as an advisor for Abbott, Ache Laboratorios Farmaceuticos S\/A, GSK, Novo Nordisk, Takeda and Roche, and provided expert testimony for Abbott. IDC is a member of SCOUT Executive Steering Committee (ESC) received payment from Abbott Laboratories, royalties from Wiley-Blackwell as co-editor of an obesity textbook, and the Boden Institute of Obesity, Nutrition and Exercise received grants from sanofi-aventis, Pfizer (Australia), Weight Watchers, Allergan and the Korean Ministry of Agriculture. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}